IDH1 and astrocytoma (excluding glioblastoma): In 2021, Platten et al. presented an exciting multicenter, single-arm, open-label, first-in-humans phase I vaccine trial carried out in 33 patients with newly diagnosed WHO grade 3 and 4 IDH1(R132H)+ astrocytomas.